Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Gains from Investment Securities (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Gains from Investment Securities data on record, last reported at $11.6 million in Q1 2026.

  • On a quarterly basis, Gains from Investment Securities fell 45.48% to $11.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $11.6 million, a 45.48% decrease, with the full-year FY2024 number at $1.1 million, up 42.52% from a year prior.
  • Gains from Investment Securities reached $11.6 million in Q1 2026 per IKT's latest filing, down from $27.2 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for IKT hit a ceiling of $27.2 million in Q3 2025 and a floor of $18039.0 in Q1 2024.
  • A 5-year average of $5.9 million and a median of $209887.0 in 2022 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: plummeted 76.18% in 2023, then soared 118139.34% in 2025.
  • Tracing IKT's Gains from Investment Securities over 5 years: stood at $76651.0 in 2022, then skyrocketed by 944.07% to $800293.0 in 2023, then soared by 42.52% to $1.1 million in 2024, then surged by 2286.98% to $27.2 million in 2025, then crashed by 57.29% to $11.6 million in 2026.
  • Business Quant data shows Gains from Investment Securities for IKT at $11.6 million in Q1 2026, $27.2 million in Q3 2025, and $25.8 million in Q2 2025.